Sign Out
Hypotension: Telmisartan: In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients, symptomatic hypotension occur alter initiation of therapy with Telmisartan.
Amlodipine: Symptomatic hypotension is possible particularly in patients with severe aortic stenosis.
Hyperkalemia: Telmisartan: Hyperkalemia may occur in plasma on ARBs particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels.
Patients with Impaired Hepatic Function: Telmisartan: Patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance.
Amlodipine: Since patients with hepatic impairment have decreased clearance of amlodipine, start amlodipine or add amlodipine at 2.5mg in patients with hepatic impairment.
Continue with Google